Scientific Sessions 2025  /  Groundbreaking Trials in Cardiometabolic Therapeutics  /  The Next Era in Cardiometabolic Treatment
Logo

American Heart Association

  81
  0

Final ID:

The Next Era in Cardiometabolic Treatment

  • Ballantyne, Christie  ( BAYLOR COLLEGE MEDICINE , Houston , Texas , United States )
    • Author Disclosures:
    Christie Ballantyne: DO have relevant financial relationships ; Researcher:merck:Active (exists now) ; Consultant:Novo Nordisk:Active (exists now) ; Researcher:Novo Nordisk:Active (exists now) ; Consultant:Arrowhead:Active (exists now) ; Researcher:Arrowhead:Active (exists now) ; Consultant:Ionis:Active (exists now) ; Researcher:Ionis:Active (exists now) ; Consultant:Amgen:Active (exists now) ; Researcher:Amgen:Active (exists now) ; Consultant:Eli Lilly:Active (exists now) ; Researcher:Eli Lilly:Active (exists now) ; Consultant:Novartis:Active (exists now) ; Researcher:Novartis:Active (exists now) ; Consultant:Merck:Active (exists now)
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Groundbreaking Trials in Cardiometabolic Therapeutics

Saturday, 11/08/2025 , 08:30AM - 09:45AM

Late-Breaking Science

More abstracts on this topic:
Effect of Evolocumab in Patients at High Cardiovascular Risk without Prior Myocardial Infarction or Stroke: Primary Results of the VESALIUS-CV trial

Bohula Erin, Wang Huei, Cyrille Marcoli, Paiva Da Silva Lima Gabriel, Giugliano Robert, Sabatine Marc, Marston Nicholas, Bhatia Ajay, De Ferrari Gaetano Maria, Leiter Lawrence, Nicolau Jose, Park Jeong-gun, Murphy Sabina, Walsh Emileigh

Discussant: VESALIUS-CV trial

Morris Pamela

More abstracts from these authors:
Targets, Tools, and Tailored Therapy: What's New and What's Next in Lipid Management for Coronary Atherosclerosis

Ballantyne Christie

Will apoCIII therapies tip the BALANCE towards targeting triglycerides?

Tsimikas Sotirios, Ballantyne Christie

You have to be authorized to contact abstract author. Please, Login
Not Available